Healthcare / BiotechnologyLSE
$0.53
-0.03 (-4.55%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-2.4M · quality 66.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$18M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-175.4%
↓Gross Margin
48.1%
↓Debt/Equity
0.36
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-33.2%
FCF CAGR
—
FCF margin
-169.2%
FCF / Net income
0.84x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.2M · net income $-2.4M · FCF $-2.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.2M | $1.2M | $860000.00 | $1.8M | $4.0M |
| Net Income | $-2.4M | $-2.4M | $-3.0M | $-7.8M | $-2.1M |
| EBITDA | $-2.3M | $-2.3M | $-2.8M | $-4.8M | $-2.1M |
| EPS | -0.00 | -0.00 | -0.01 | -0.11 | -0.03 |
| Gross Margin | 48.1% | 48.1% | 29.1% | 20.5% | 66.5% |
| Operating Margin | -219.9% | -219.9% | -364.0% | -465.6% | -63.8% |
| Net Margin | -201.5% | -201.5% | -344.0% | -447.3% | -51.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.36 | 0.36 | 0.92 | 3.55 | 0.16 |
| Current Ratio | 2.04 | 2.04 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.0M | $-2.0M | $-2.4M | $-6.1M | $-2.8M |
| Returns | |||||
| ROE | -175.4% | -175.4% | -333.5% | -2577.6% | -26.0% |
| Valuation | |||||
| P/B | 715.44 | 715.44 | 315.89 | 1135.78 | 769.65 |
| Growth & Yield | |||||
| Revenue Growth | 39.9% | 39.9% | -50.9% | -56.6% | — |
| EPS Growth | 80.3% | 80.3% | 93.7% | -250.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+52.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → -0.00
Residual
+52.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.